Poltreg SA is a clinical stage SME that develops cellular therapy with T regulatory cells (Tregs) in the treatment of autoimmune diseases. The company is a spin-off of the Medical University of Gdańsk where the research started in 1999.
We are currently preparing for phase III trial in type 1 diabetes in children (phase II to be completed in 3rd Q 2019), phase II in multiple sclerosis (phase I to be completed in 2rd Q 2019) and prepare for phase I in rheumatoid arthritis. There is also ongoing preclinical work with new antigen-specific preparation of Tregs.
Therapy with FoxP3+ T regulatory cells (Tregs) utilizes natural immunosuppressive potential of patient's cells. Tregs are obtained from the patient’s blood, expanded under GMP conditions to high numbers and administered back. In the body, Tregs inhibit autoaggressive lymphocytes capable of destroying self tissues (pancreatic islets in diabetes, myelin sheaths of neurones in multiple sclerosis, joints in rheumatoid arthritis). This way, the treatment stops or delays the progression of autoimmune diseases.
Our preparation of Tregs is classified as ATMP (advanced therapy medicinal product) by European Medicines Agency. We are currently in dialogue with EMA to obtain centralised marketing authorisation for the product.